Puma Biotechnology (NASDAQ:PBYI) received a $147.00 price target from Credit Suisse Group in a research report issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 60.48% from the stock’s current price.

Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, January 15th. Citigroup restated a “buy” rating and issued a $164.00 target price on shares of Puma Biotechnology in a report on Wednesday, January 3rd. ValuEngine lowered shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, Barclays restated a “buy” rating and issued a $122.00 target price (up previously from $103.00) on shares of Puma Biotechnology in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $131.22.

Puma Biotechnology (PBYI) traded up $3.35 during mid-day trading on Monday, reaching $91.60. 640,800 shares of the company traded hands, compared to its average volume of 668,223. The firm has a market capitalization of $3,500.00, a price-to-earnings ratio of -11.18 and a beta of 0.72. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the previous year, the firm earned ($1.11) EPS. equities research analysts anticipate that Puma Biotechnology will post -8.17 EPS for the current year.

In other news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 21.10% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its holdings in shares of Puma Biotechnology by 5.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Puma Biotechnology by 2.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 437 shares during the period. California Public Employees Retirement System raised its holdings in shares of Puma Biotechnology by 0.7% during the third quarter. California Public Employees Retirement System now owns 108,000 shares of the biopharmaceutical company’s stock valued at $12,933,000 after purchasing an additional 800 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Puma Biotechnology by 13.5% during the second quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 936 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Puma Biotechnology by 3.1% during the third quarter. Rhumbline Advisers now owns 34,794 shares of the biopharmaceutical company’s stock valued at $4,167,000 after purchasing an additional 1,061 shares during the period. Hedge funds and other institutional investors own 95.86% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://theolympiareport.com/2018/01/22/credit-suisse-group-reiterates-147-00-price-target-for-puma-biotechnology-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.